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n recent years, a growing number of clinics in Australia
and overseas have begun to offer therapies that claim to
restore health by using stem cells to replace or repair
the patient's faulty or missing cells. For those who have
been told that conventional medicine has nothing more
to offer, a visit to a stem cell clinic may appear to be worth the
time, effort and expense that this entails. 
The reality, sadly, is very different. Most people are unlikely
to benefit, losing precious time, money, hope and trust in the
course of pursuing this new form of medical tourism. 
What’s on Offer?
Stem cell tourism is a phrase used to encompass travel – usually
overseas – for a wide range of therapies involving stem cells.
These therapies may involve the use of the patient’s own (autol-
ogous) stem cells from fat or their bone marrow, or donated
stem cells from cord blood, embryos and foetal tissue.
Therapy might be administered by having the patient inhale
the cells, or by injecting the cells under the skin, into a vein or
joint, directly into the fluid around the spinal cord or into the
patient’s brain. Such therapies have been touted as effective
treatments for many conditions and illnesses including arthritis,
spinal cord injury, motor neurone disease, multiple sclerosis, cere-
bral palsy, neurodegenerative conditions and autism. Often
the same treatment is offered for conditions with vastly different
underlying pathology. 
Unlike other forms of medical tourism – such as travel for
IVF, cosmetic surgery, joint replacement or dentistry, which
are based on access to well-established conventional therapies
that are available more quickly and at a more affordable price
than in the patient’s home country – stem cell tourism provides
patients with access to “treatments” that are yet to be proven.
These treatments are not based upon rigorous scientific evidence,
have not been clearly demonstrated to offer any benefit, and
are not recognised or reimbursed by local health systems. 
Although it may one day be possible to manufacture replace-
ment cells to restore function to diseased or damaged organs, to
date there remain few recognised stem cell therapies beyond the
use of blood and bone marrow stem cell transplantation  for the
treatment of leukaemia, lymphoma and other diseases of the blood
and immune system. While new stem cell-based treatments are
being evaluated in clinical trials across the globe, the “therapies”
offered by stem cell clinics are well outside this framework.
Not only are the benefits yet to be established, but the ther-
apies offered also come with possible health risks. The cells are
usually prepared “in-house” rather than in an accredited labo-
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ratory with independent verification of exactly what cells, if
any, are present in the solution administered to the patient.
Some clinics also grow the cells in their laboratories, increasing
the risk of infection and/or fundamentally changing the prop-
erties of the cells.
While complications are fortunately rare, they have been
reported. For example, a Beverly Hills patient who had received
a “stem cell” face-lift developed shards of bone around one of
her eyes when the doctor mixed dermal filler, a commonly used
reagent in cosmetic surgery, with the stem cells – turning them
from fat to bone. 
Deaths have also been reported overseas. In one case a young
man who was left paralysed following a motorbike accident
died when his stem cell treatment caused a range of complica-
tions, including increased pressure in his skull and brain. 
Even if they don’t cause direct physical harms, these unproven
stem cell treatments are expensive and may pose a significant
financial burden for many patients and their families – partic-
ularly at a time when many people are not working and are
already experiencing the financial strain of chronic or life-
threatening illness. 
Patients pursuing stem cell treatments may also be diverted
from existing and established healthcare, thereby compromising
their long-term prognosis and ultimately limiting the options
that may be available to them and to their family.
Stem Cell Tourism in Australia 
Until recently, the key destinations for stem cell tourism were
countries with little infrastructure and oversight of medical
practices, such as China, Mexico, Ukraine, the Bahamas, Thai-
land and India. More recently, however, countries with high
levels of healthcare and stringent rules and regulations governing
medical practice, such as Australia and the USA, have become
attractive destinations for stem cell tourism. 
While the bulk of the doctors at Australian stem cell clinics
restrict their services to treating osteoarthritis and other joint
problems – extracting the patient’s own cells and injecting
them back into the affected joint, often on the same day –
others “treat” a wide range of medical conditions from migraine
to Parkinson’s disease, multiple sclerosis and even dementia.
Generally, these unproven autologous treatments are given
intravenously, but in at least one Australian clinic, stem cells are
injected directly into the fluid surrounding the patient’s spinal
cord and brain. 
In most cases, the stem cell treatment does not involve a
single injection, but rather a “course” of treatments – particu-
larly when a benefit is not apparent after the first treatment. 
Clinics also offer other services to prospective clients
including accommodation, concierge services, massage, relax-
ation therapies and proximity to airports, making them readily
accessible to interstate and international “tourists”. All of this
comes at a cost. Because these treatments receive no Medicare
rebate or private health insurance refund, the out-of-pocket
costs can be around $10,000 for each treatment. On any
reading, this is a substantial amount of money to pay for a
treatment that has not been shown to be effective and isn’t
offered as part of standard healthcare or within the context
of a clinical trial. 
Misleading Rhetoric
It could be argued that those pursuing stem cell therapies are
chasing an illusion – the false promise of therapeutic benefit.
This does not mean, however, that they are foolish or misguided;
rather, their choices can be understood as a result of the situa-
tion that their illness has placed them in, together with inten-
sive advertising on the part of stem cell clinics and misleading
media coverage of stem cell “science”.
The websites and other advertising material used by stem
cell clinics, both locally and overseas, are steeped in rhetoric of
hope and claims of benefit – highlighting testimonials of grateful
patients and favourable media stories. They also emphasise the
innovative or “cutting-edge” nature of the treatments on offer,
and imply that the doctors and scientists working in the clinics
are medical pioneers or leading experts in their field. 
What is made much less clear is the lack of evidence for these
treatments, the potential risks involved and the high costs of care.
To the patient, who fears the inevitable pace of illness or the
prospect of death, stem cell clinics may therefore appear to
offer the only chance to restore their health and well-being. 
Another reason that stem cell therapies have become so popular
is that stem cell “breakthroughs” feature prominently in both
mainstream and social media, fuelling the perception that stem
cells are synonymous with a “cure”. Indeed, it has never been
easier for patients to find out what medical science may promise,
what treatment options are open to them and what they can
purchase to improve their health. Type “stem cells treatments”
into your favourite search engine and you will be presented with
a long list of stem cell clinics that are prepared to treat you. 
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Ambiguous Regulatory Processes 
Irrespective of whether stem cell clinics are based in China or
Australia, all of them operate by exploiting a “grey zone” of
medical practice. By positioning unproven stem cell treatments
as “innovative” medical care, those who want to offer these
treatments argue that this is reasonable because it may provide
patients with a benefit and because patients have a “right” to
pursue novel “treatments”. 
As well as confusing innovation with research, such posi-
tioning conveniently ignores the inherent conflict of interest
for the doctor who may appear to be helping the patient make
an informed choice about their options, but is also likely to
financially gain if the patient elects to pursue stem cell treatment.
Such practices are also in stark contrast to the safeguards in
place for clinical trials, where those seeking to test an experi-
mental therapy would have to justify the scientific basis of the
proposed research, seek independent review of the research
protocol and the strategies in place to recruit, select, inform
and care for the research participants, and ensure that patient-
participants are neither financially penalised for participation
or coerced by the prospect of payment. 
Ambiguity also surrounds the governance and regulation of
stem cell clinics. On the one hand, it would be expected that
health professionals performing the treatments would be regu-
lated by the medical and nursing boards responsible for the
conduct of health professionals. In addition, because stem cell
treatments can be regarded as a medical product, one might
also expect that they would be subject to the laws governing
therapeutic goods.
However, at present, providers of unproven stem cell treat-
ments, especially those utilising the patient’s own cells, appear
to operate in a gap between these two modes of regulation. For
example, in Australia there is no requirement for stem cell clinics
to meet manufacturing standards that would usually be expected
in the production of a cell-based product. All that is needed is
for the treatment to be performed by a doctor registered in
Australia and for the doctor to use the patient’s own cells. 
In response to concerns raised about these practices, the
Australian Therapeutic Goods Administration (TGA)
conducted a public consultation in early 2015 to explore ways
to better regulate autologous cell-based therapies. The TGA
is yet to announce the outcome of the consultation. 
Groups such as the International Society for Stem Cell
Research and the International Society for Cell Therapy have
also been critical of both local clinics and of stem cell tourism,
and have called for the adoption of tighter regulations and
professional standards. Despite this, the number of stem cell
clinics continues to increase, both in Australia and overseas. 
The Illusion of Choice 
Access to stem cell treatments is often promoted as a right,
particularly for those who appear to have no other option for
treatment of their disease. While the language of “rights” has
strong rhetorical force, it is difficult for patients to make an
informed choice about stem cell treatments when both the
benefits and risks of treatment are uncertain and/or unproven,
and when many clinics make anecdotal and unsubstantiated
claims that patients “improve” with treatment. While this may
be good for business, it is poor science and does nothing to
facilitate genuine informed choice. 
While patient choice must remain paramount in this and
other forms of medical practice, the current unfettered commer-
cial environment that has allowed stem cell tourism to flourish
must be challenged, and the professionals who enable it should
be held to account. Healthcare, irrespective of our desire to
support innovation and scientific advances, must continue to
be underpinned by evidence and ethical practice, and not simply
by profit.
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